论文部分内容阅读
同抗体药物相比,非免疫球蛋白配体药物(Non-immunoglobulin scaffolds,非免蛋白配体药物)具有分子量小,不需要翻译后修饰,通常缺乏二硫键,并可进行直接的多聚化修饰等优点。最近几年,研发的非免蛋白配体药物种类就达到了二十余种,如Adhirons,Alphabodies,Centyrins,Pronectins,Repebodies,Affimers,和Obodies等,其中的139个非免疫球蛋白配体,可以特异靶向结合102种蛋白。这些非免疫球蛋白配体多用于癌症和炎症性疾病的治疗和诊断,其中有10多种非免疫球蛋白配体已经进入临床试验研究。最近,非免蛋白配体也被用于伴侣蛋白作结构解析研究,翻译后修饰的细胞内监控,或作为显微镜,流式细胞仪,Western印迹法等检测方法中抗体的替代品。
Non-immunoglobulin scaffolds (non-immunoglobulin scaffolds), which have a small molecular weight, do not require post-translational modifications, usually lack a disulfide bond, and allow for direct multimerization as compared to antibody drugs Modification and so on. In recent years, the research and development of non-immune protein ligands to achieve more than 20 kinds of species, such as Adhirons, Alphabodies, Centyrins, Pronectins, Repebodies, Affimers, and Obodies and so on, of which 139 non-immunoglobulin ligands, Specifically targeted to bind 102 proteins. These non-immunoglobulin ligands are mostly used in the treatment and diagnosis of cancer and inflammatory diseases, of which more than 10 non-immunoglobulin ligands have entered clinical trials. More recently, nonimmunoglobulin ligands have also been used as chaperones for structural elucidation studies, post-translational modification of intracellular monitoring, or as an alternative to antibodies in assays such as microscopy, flow cytometry, Western blotting and the like.